Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography

[1]  D. Tracey,et al.  Neurotransmitters in the Human Brain , 2012, Advances in Behavioral Biology.

[2]  M. Glass,et al.  The therapeutic potential of G-protein coupled receptors in Huntington's disease. , 2010, Pharmacology & therapeutics.

[3]  Moussa B. H. Youdim,et al.  Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity , 2010, Progress in Neurobiology.

[4]  M. Naoi,et al.  Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. , 2010, Current pharmaceutical design.

[5]  S. Carradori,et al.  Focusing on new monoamine oxidase inhibitors , 2010, Expert opinion on therapeutic patents.

[6]  S. Stahl,et al.  Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants , 2008, CNS Spectrums.

[7]  J. Andersen,et al.  MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology , 2008, PloS one.

[8]  D. Blum,et al.  3‐Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease , 2005, Journal of neurochemistry.

[9]  Jian-jun Wang,et al.  Excitatory effect of histamine on neuronal activity of rat globus pallidus by activation of H2 receptors in vitro , 2005, Neuroscience Research.

[10]  Allison Doerr.  A trinucleotide repeat biosensor , 2005, Nature Methods.

[11]  R. Ferrante,et al.  Emerging chemotherapeutic strategies for Huntington’s disease , 2005, Expert opinion on emerging drugs.

[12]  G. Peluso,et al.  Huntingtons Disease: New Frontiers for Molecular and Cell Therapy , 2005 .

[13]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[14]  J. Arias-Montaño,et al.  Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices , 2004, Neuroscience Letters.

[15]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[16]  Michael Dragunow,et al.  Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Curtis,et al.  Neurogenesis in the Diseased Adult Human Brain: New Therapeutic Strategies for Neurodegenerative Diseases , 2003, Cell cycle.

[18]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[19]  P. Gasque,et al.  Increased Complement Biosynthesis By Microglia and Complement Activation on Neurons in Huntington's Disease , 1999, Experimental Neurology.

[20]  R. Faull,et al.  Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABAA receptor changes , 1999, Journal of Chemical Neuroanatomy.

[21]  J. Saura,et al.  Biphasic and Region-Specific MAO-B Response to Aging in Normal Human Brain , 1997, Neurobiology of Aging.

[22]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[23]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[24]  I. Winship,et al.  Molecular analysis of the Huntington's disease gene in New Zealand. , 1996, The New Zealand medical journal.

[25]  P. Malherbe,et al.  Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry , 1996, Neuroscience.

[26]  S. Folstein,et al.  Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.

[27]  V. Chan‐Palay,et al.  Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography , 1994, Neuroscience.

[28]  R. Faull,et al.  Loss of cannabinoid receptors in the substantia nigra in huntington's disease , 1993, Neuroscience.

[29]  G. Doucet,et al.  Ultrastructure and synaptic targets of the raphe-nigral projection in the rat , 1993, Neuroscience.

[30]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[31]  J. Saura,et al.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[33]  R H Myers,et al.  Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.

[34]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  J. Shih,et al.  Human monoamine oxidase A and B genes exhibit identical exon-intron organization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Seeburg,et al.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. M. Rose,et al.  Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem , 1988, Neuroscience.

[38]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[39]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[40]  X. Breakefield,et al.  Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Gaspar,et al.  l‐Histidine Decarboxylase in the Human Brain: Properties and Localization , 1980, Journal of neurochemistry.

[42]  J. Caboche,et al.  Huntington's disease. , 2010, Advances in experimental medicine and biology.

[43]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[44]  J. Mann,et al.  Elevated postmortem monoamine oxidase B activity in the caudate nucleus in hUntington's disease compared to schizophrenics and controls , 2005, Journal of Neural Transmission.

[45]  H. Kimura,et al.  Expression of monoamine oxidase B activity in astrocytes of senile plaques , 2004, Acta Neuropathologica.

[46]  M. Head,et al.  The Neuropathology of Dementia: Human prion diseases , 2004 .

[47]  H. Zoghbi,et al.  Trinucleotide repeats: mechanisms and pathophysiology. , 2000, Annual review of genomics and human genetics.

[48]  P. Malherbe,et al.  Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. , 1998, Journal of neural transmission. Supplementum.

[49]  H. Kremer.  Unified Huntington's disease rating scale: reliability and consistency , 1996 .

[50]  M. Dragunow,et al.  Huntington’s Disease and Neural Transplantation: GABAA Receptor Changes in the Basal Ganglia in Huntington’s Disease in the Human Brain and in the Quinolinic Acid Lesioned Rat Model of the Disease Following Fetal Neuron Transplants , 1995 .

[51]  J. Gusella,et al.  Huntington's disease. , 1995, Seminars in cell biology.

[52]  R. Faull,et al.  The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. , 1993, Progress in brain research.

[53]  A. Cesura,et al.  The new generation of monoamine oxidase inhibitors. , 1992, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.